Abbott LaboratoriesXSWX:ABT 76 Debt-to-EBITDA is 3.51 as of Mar. 2026, which is 87% above its 10-year median of 1.88. GuruFocus rates XSWX:ABT with a GF Score™ of 76/100 and a GF Value™ of CHF107.55. Among 470 Medical Devices & Instruments companies, Abbott Laboratories ranks worse than 68.72% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Abbott Laboratories's Debt-to-EBITDA or its related term are showing as below:
XSWX:ABT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.15 Med: 1.88 Max: 6.88
Current: 2.88
During the past 13 years, the highest Debt-to-EBITDA Ratio of Abbott Laboratories was 6.88. The lowest was 1.15. And the median was 1.88.
XSWX:ABT's Debt-to-EBITDA is ranked worse than 68.72% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs XSWX:ABT: 2.88
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Abbott Laboratories Debt-to-EBITDA Related Terms
Abbott Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABT vs SYK, MDT, BSX: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Abbott Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Abbott Laboratories (XSWX:ABT) has a Debt-to-EBITDA of 3.51 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Abbott Laboratories. This is 87% above median its historical median of 1.88. Over the past decade, Abbott Laboratories' Debt-to-EBITDA has ranged from 1.15 to 6.88. According to the industry distribution chart, Abbott Laboratories ranks #323 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 68.7%.
Is Abbott Laboratories' Debt-to-EBITDA too high?
Abbott Laboratories' current Debt-to-EBITDA of 3.51 is 87% above median its 10-year median of 1.88. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 6.88. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. Abbott Laboratories' value of 3.51 is 121.5% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #323 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Debt-to-EBITDA compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #323 out of 470 companies for Debt-to-EBITDA. This places Abbott Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. Abbott Laboratories' value of 3.51 is 121.5% above this benchmark. Historically, Abbott Laboratories' own Debt-to-EBITDA has ranged from 1.15 to 6.88 over the past decade. While the company's 10-year median is 1.88 vs. the industry median of 1.59, Abbott Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current Debt-to-EBITDA of 3.51 is 121.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Abbott Laboratories. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current Debt-to-EBITDA is 3.51, which is 87% above median its own 10-year median of 1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Debt-to-EBITDA of 3.51. The stock's GF Value™ is CHF107.55, compared to a current price of CHF77.50 — trading 27.9% below its estimated fair value. The current Debt-to-EBITDA is 3.51, which is 87% above median its 10-year median of 1.88 and 121.5% above the Medical Devices & Instruments industry median of 1.59. Abbott Laboratories' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Debt-to-EBITDA is 3.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF77.50 is trading 27.9% below its estimated GF Value™ of CHF107.55.
Key valuation signals for XSWX:ABT:
Debt-to-EBITDA: 3.51 (87% above median its 10-year median of 1.88)
GF Value™: CHF107.55 vs. price of CHF77.50 (27.9% below fair value)
Industry Position: 121.5% above the Medical Devices & Instruments median (#323 of 470)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
76GF Score
Get the complete analysis for XSWX:ABT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
